icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
R9jBht8cgzqyBpHa
Listen
